Breast cancer progression is a complex process controlled by genetic and epigenetic factors
that coordinate the crosstalk between tumor cells and the components of tumor …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved
for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and …

Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …

About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do
not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment …

Breast cancer was traditionally not considered a particularly immunogenic tumor. However,
recent developments have shown that some aggressive triple-negative breast cancers are …

Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer.
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone …

Abstract Background Chemotherapy (CT), radiotherapy (RT), and chemoradiotherapy (CRT)
are able to alter the composition of the tumor immune microenvironment (TIME) …

Cancer immunotherapy has evolved dramatically with improved understanding of immune
microenvironment and immunosurveillance. The immunogenicity of breast cancer is rather …

Purpose: We aim to evaluate the prognostic significance of tumor-infiltrating lymphocyte on
residual disease (RD-TIL) in HER2+ patients with breast cancer who failed to achieve …